Gaudinski / GSK / VRC07-523LS: 2019 Pi on VRC07
Post# of 153834
(Total Views: 6846)
Posted On: 10/20/2024 12:13:13 AM
Gaudinski / GSK / VRC07-523LS:
2019 Pi on VRC07-533LS dosing trial of non-HIV humans:
Well tolerated.
" Future studies are necessary to evaluate VRC07–523LS for prevention and treatment in HIV-1 infected individuals, as well as in future combination trials"
https://www.researchgate.net/publication/3354...ical_trial
____
He's from GSK:
https://www.linkedin.com/in/martin-gaudinski-367144bb
___
* VRC07-523LS bNab is used in our LL-PLS
* His trial was not of large scale of course, but it gives us preliminary human data of age 18-50, for our FcRn collaboration.
* Oct. 2021 ViiV bought the rights from Shionogi.
Haven't found yet the original FcRn / LL-PLS project start date.
My guess at earliest 2022.
After ViiV took control of VRC07-523LS.
2022, clinical hold & CRO.
CEO ousted.
Non yet, have a direct affect on developing FcRn LL-PLS.
It is 3rd party funded.
March 2024 FDA hold lifted.
July 9th, 2024 settlement that Dr. J said allows the company to move forward on it's plans.
Shareholders were surprised @ $12m but trusted for good business reasons.
3 months later:
Oct. 7th, 2024 FcRn news.
Oct. 8th, 2024 Dr. Lataillade.
Airports tell you not to pick-up or carry unknown bags.
1st positive cash flow -- .02
No new shares request.
No reverse split.
Cytodyn's old baggage has been dropped.
Max Lataillade boarded Cytodyn with new & improved luggage.
Packed with iP & a platform drug.
Just the way titans of an industry make moves.
2019 Pi on VRC07-533LS dosing trial of non-HIV humans:
Well tolerated.
" Future studies are necessary to evaluate VRC07–523LS for prevention and treatment in HIV-1 infected individuals, as well as in future combination trials"
https://www.researchgate.net/publication/3354...ical_trial
____
He's from GSK:
https://www.linkedin.com/in/martin-gaudinski-367144bb
___
* VRC07-523LS bNab is used in our LL-PLS
* His trial was not of large scale of course, but it gives us preliminary human data of age 18-50, for our FcRn collaboration.
* Oct. 2021 ViiV bought the rights from Shionogi.
Haven't found yet the original FcRn / LL-PLS project start date.
My guess at earliest 2022.
After ViiV took control of VRC07-523LS.
2022, clinical hold & CRO.
CEO ousted.
Non yet, have a direct affect on developing FcRn LL-PLS.
It is 3rd party funded.
March 2024 FDA hold lifted.
July 9th, 2024 settlement that Dr. J said allows the company to move forward on it's plans.
Shareholders were surprised @ $12m but trusted for good business reasons.
3 months later:
Oct. 7th, 2024 FcRn news.
Oct. 8th, 2024 Dr. Lataillade.
Airports tell you not to pick-up or carry unknown bags.
1st positive cash flow -- .02
No new shares request.
No reverse split.
Cytodyn's old baggage has been dropped.
Max Lataillade boarded Cytodyn with new & improved luggage.
Packed with iP & a platform drug.
Just the way titans of an industry make moves.
(6)
(0)